Asset profile
CJC-1134-PC
Peptide
Evidence outlook · lead readout
NCT07057271 · Type 2 Diabetes Mellitus - Poor Control
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT07057271: The trial was randomized, quadruple-blind, and placebo-controlled, with 464 participants. However, its primary endpoint was the surrogate measure HbA1c rather than a hard clinical outcome, and no primary endpoint results are posted.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 24 direct rivals (same mechanism and indication), 26 same-class, 60 same-indication; 34 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CJC-1134-PC: this drug | Phase 3 | Peptide | GLP-1 receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | ||
| HDG1901 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HSK7653 | Phase 3 | Small molecule | GLP-1 receptor | ||
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
18 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.